RBC Capital upgraded Sage Therapeutics (SAGE) to Sector Perform from Underperform with an unchanged price target of $4.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reported another clinical setback, says H.C. Wainwright
- Sage Therapeutics reports results from Phase 2 DIMENSION Study
- Acumen appoints Schacterle as Chief Regulatory Officer, Head of Quality
- Sage Therapeutics price target lowered to $9 from $11 at Morgan Stanley
- SAGE Therapeutics Announces Strategic Reorganization Amid Executive Departures